Next Day Disclosure Return
Filed with HKEX · Stock code 6996 · · 5 pages · English
Antengene Corporation Limited on 6ix
Earlier from Antengene
- Antengene to Present Latest Preclinical Results of Novel Cos-TCE Platform in Rapid Oral Abstract Presentation at SITC 2026
- 2026 Interim report
- Antengene Announces First Patient Dosed in Pivotal Phase III CLINCH-3 Study of ATG-022
- Antengene Publishes Preclinical Research Paper on CD73 Small Molecule Inhibitor ATG-037 Combined with Selinexor in Cancer Gene Therapy
- Antengene Receives Clinical Trial Approval in Australia for Phase I ATTRACT Study of ATG-201 (CD19 x CD3 TCE) in B Cell-related Autoimmune Diseases
Later from Antengene
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Antengene to Present Latest Preclinical Results of ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at ACR 2026
Follow Antengene into a list and get an email when it puts out news.
Follow Antengene